Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
emflaza
Synonyms :
deflazacort
Class :
corticosteroid
Brand Name :
emflaza
Synonyms :
deflazacort
Class :
corticosteroid
Dosage Forms & StrengthsÂ
TabletÂ
6mgÂ
18mgÂ
30mgÂ
36mgÂ
Oral suspensionÂ
22.75mg/mlÂ
0.9
mg/kg
Tablet
Orally 
every day
Dosage Forms & StrengthsÂ
TabletÂ
6mgÂ
18mgÂ
30mgÂ
36mgÂ
Oral suspensionÂ
22.75mg/mlÂ
0.9
mg/kg
Tablet
Orally 
every day
may increase the immunosuppressive effect of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may decrease the diagnostic effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
measles, mumps, rubella, and varicella vaccine, live (Rx)
may decrease the therapeutic effect of corticosteroids
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
vaccinia immune globulin intravenous (Rx)
may decrease the therapeutic effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the serum concentration
may decrease the anti-neoplastic effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the adverse effects of corticosteroids
may increase the anti-coagulant effect of corticosteroids
may enhance the serum concentration of CYP3A4 substrates
may decrease the diagnostic effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may increase the adverse effects of corticosteroids
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
deflazacort: they may diminish serum concentrations of CYP3A4 Inducers
deflazacort: they may diminish serum concentrations of CYP3A4 Inducers
when deflazacort is used in combination with diphtheria & tetanus toxoids, this leads to a reduction in the effects of diphtheria & tetanus toxoids through pharmacodynamic antagonism
nafcillin will decrease the effect of action of deflazacort by affecting enzyme CYP3A4 metabolism.
the effect of nivolumab decreases on interacting with deflazacort.
the effect of deflazacort is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of deflazacort
pneumococcal vaccine polyvalentÂ
the activity of pneumococcal vaccine polyvalent is reduced due to pharmacodynamic antagonism
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may diminish the absorption of corticosteroids
may increase the toxic effect of corticosteroids
may increase the toxic effect of corticosteroids
It may diminish the serum potassium levels when combined with sodium acid phosphate
may diminish the pharmacodynamic antagonistic effect of each other when combined
measles, mumps, rubella, and varicella vaccine, live 
may diminish the pharmacodynamic antagonistic effect of each other when combined
measles mumps and rubella vaccine, live
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
smallpox (vaccinia) vaccine, live
may diminish the pharmacodynamic antagonistic effect of each other when combined
When deflazacort is used together with ridaforolimus, this leads to enhanced concentration serum of deflazacort
When deflazacort is used in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk of adverse effects  
may decrease the serum concentration of each other
the therapeutic activity of deflazacort may be reduced
the serum levels of deflazacort may be increased
When deflazacort is used together with lomitapide, this leads to an enhancement in lomitapide’s metabolism
serum potassium will lower when dfalzacort is combinely used with sterculia
When deflazacort is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Frequency defined:Â Â
>10%Â
Increase in weightÂ
Upper respiratory tract infectionÂ
PollakiuriaÂ
Cushingoid appearanceÂ
Increased appetiteÂ
CoughÂ
1-10%Â
HirsutismÂ
ErythemaÂ
IrritabilityÂ
Abdominal discomfortÂ
DyspepsiaÂ
ThirstÂ
NauseaÂ
InfluenzaÂ
Urinary tract infectionÂ
Neck painÂ
Muscle spasmsÂ
Testicular painÂ
HypoventilationÂ
AlopeciaÂ
DysuriaÂ
DizzinessÂ
Irregular heart rateÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknown Â
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: deflazacortÂ
Pronounced: de·flaza·cortÂ
Why do we use deflazacort?Â
It is used to treat Duchenne muscular dystrophyÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
